MX2016015641A - Compuesto de pirrolidina novedoso, y aplicación como agonista del receptor de melanocortina. - Google Patents

Compuesto de pirrolidina novedoso, y aplicación como agonista del receptor de melanocortina.

Info

Publication number
MX2016015641A
MX2016015641A MX2016015641A MX2016015641A MX2016015641A MX 2016015641 A MX2016015641 A MX 2016015641A MX 2016015641 A MX2016015641 A MX 2016015641A MX 2016015641 A MX2016015641 A MX 2016015641A MX 2016015641 A MX2016015641 A MX 2016015641A
Authority
MX
Mexico
Prior art keywords
optionally substituted
receptor agonist
novedous
pirrolidine
composite
Prior art date
Application number
MX2016015641A
Other languages
English (en)
Other versions
MX386063B (es
Inventor
Yasuo Yamamoto
Sato Atsushi
Kenji Morokuma
Hiroaki Shitama
Adachi Takashi
MIYASHIRO Masahiko
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2016015641A publication Critical patent/MX2016015641A/es
Publication of MX386063B publication Critical patent/MX386063B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un compuesto de pirrolidina novedoso que tiene actividad agonista del receptor de melanocortina o una sal farmacéuticamente aceptable del mismo, y a aplicaciones farmacéuticas del mismo; la presente invención se refiere a un derivado de pirrolidina representado por la fórmula (I) (ver Fórmula) en donde el anillo A representa un grupo arilo opcionalmente sustituido o similares; R1 representa un grupo alquilo opcionalmente sustituido o similares; R2 representa un átomo de halógeno, o similares; y R3 es un grupo alquilo sustituido con un grupo arilo opcionalmente sustituido o similares, y R4 es un átomo de hidrógeno, o similares; o R3 y R4 están unidos terminalmente entre sí, y junto con el átomo de nitrógeno al cual están unidos, forman un anillo heterocíclico alifático opcionalmente sustituido que contenía nitrógeno que puede contener parcialmente un doble enlace; o una sal farmacéuticamente aceptable del mismo.
MX2016015641A 2014-05-29 2015-05-28 Compuesto de pirrolidina novedoso, y aplicación como agonista del receptor de melanocortina. MX386063B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014111378 2014-05-29
PCT/JP2015/065469 WO2015182723A1 (ja) 2014-05-29 2015-05-28 新規ピロリジン化合物およびメラノコルチン受容体作動薬としての用途

Publications (2)

Publication Number Publication Date
MX2016015641A true MX2016015641A (es) 2017-08-04
MX386063B MX386063B (es) 2025-03-18

Family

ID=54699046

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015641A MX386063B (es) 2014-05-29 2015-05-28 Compuesto de pirrolidina novedoso, y aplicación como agonista del receptor de melanocortina.

Country Status (18)

Country Link
US (1) US9981960B2 (es)
EP (1) EP3150578B1 (es)
JP (1) JP6377736B2 (es)
KR (1) KR101919680B1 (es)
CN (2) CN106458887B (es)
AU (1) AU2015268505C1 (es)
CA (1) CA2950072C (es)
DK (1) DK3150578T3 (es)
ES (1) ES2841308T3 (es)
HU (1) HUE052714T2 (es)
MX (1) MX386063B (es)
MY (1) MY193597A (es)
PH (1) PH12016502358B1 (es)
PL (1) PL3150578T3 (es)
PT (1) PT3150578T (es)
SG (1) SG11201609864UA (es)
TW (1) TWI669301B (es)
WO (1) WO2015182723A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180032585A (ko) 2015-08-04 2018-03-30 아스테라스 세이야쿠 가부시키가이샤 피페라진 유도체
ES2869229T3 (es) * 2015-11-27 2021-10-25 Mitsubishi Tanabe Pharma Corp Derivados de 2-(((pirrolidin-3-il)carbonil)amino)-1H-imidazol como agonistas del receptor de melanocortina 1 (MCR1) para tratar la artritis reumatoide
EP3578545B1 (en) 2017-01-31 2023-07-26 Mitsubishi Tanabe Pharma Corporation Method for producing optically active pyrrolidine compounds
JP6986565B2 (ja) * 2017-09-29 2021-12-22 田辺三菱製薬株式会社 光学活性ピロリジン化合物及びその製造方法
WO2020060983A2 (en) 2018-09-18 2020-03-26 Palatin Technologies, Inc. Orally active melanocortin receptor-4 compounds
MA54619A (fr) * 2018-12-28 2021-11-03 Mitsubishi Tanabe Pharma Corp Cristal de composé d'acide pyrophosphorique
FI3953327T3 (fi) 2019-11-07 2024-01-31 Lg Chemical Ltd Melanokortiini-4-reseptoriagonisteja
IL298951A (en) * 2020-06-10 2023-02-01 Mitsubishi Tanabe Pharma Corp Prophylactic or therapeutic agent for photodermatosis
US20230248713A1 (en) * 2020-06-10 2023-08-10 Mitsubishi Tanabe Pharma Corporation Prophylactic or therapeutic agent for porphyria
WO2021251450A1 (ja) 2020-06-10 2021-12-16 田辺三菱製薬株式会社 ポルフィリン症の予防又は治療剤
WO2022053570A1 (en) 2020-09-09 2022-03-17 Clinuvel Pharmaceuticals Ltd (Uk) Pyrrolidine compounds to treat xeroderma pigmentosum
US20240059652A1 (en) * 2020-12-22 2024-02-22 Lg Chem, Ltd. Amorphous melanocortin receptor agonist and method for preparing same
KR102394875B1 (ko) * 2021-05-11 2022-05-06 주식회사 비드테크 피롤리딘을 링커로 포함하는 화합물 및 이를 포함하는 약학 조성물
KR20240145490A (ko) 2022-01-31 2024-10-07 미쓰비시 타나베 파마 코퍼레이션 멜라노코르틴 1 수용체 아고니스트의 신규 용도
CN119654150A (zh) 2022-08-03 2025-03-18 田边三菱制药株式会社 含有1-｛2-[（3s,4r）-1-｛[（3r,4r）-1-环戊基-3-氟-4-（4-甲氧基苯基）吡咯烷-3-基]羰基｝-4-（甲氧基甲基）吡咯烷-3-基]-5-（三氟甲基）苯基｝哌啶-4-甲酸或其药学上可接受的盐或者共晶的药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6294561B1 (en) 1999-12-23 2001-09-25 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
JP4104983B2 (ja) * 2001-02-28 2008-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体
WO2004078717A1 (en) * 2003-03-03 2004-09-16 Merck & Co., Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
GB0402492D0 (en) * 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
TWI332501B (en) 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
KR20080007046A (ko) * 2006-07-14 2008-01-17 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
AU2007300529A1 (en) * 2006-09-27 2008-04-03 Merck Sharp & Dohme Corp. Acylated piperidine derivatives as melanocortin-4 receptor modulators
AR073578A1 (es) 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas

Also Published As

Publication number Publication date
TWI669301B (zh) 2019-08-21
JP6377736B2 (ja) 2018-08-22
CN112194649A (zh) 2021-01-08
CA2950072C (en) 2019-03-26
WO2015182723A1 (ja) 2015-12-03
KR101919680B1 (ko) 2018-11-16
CA2950072A1 (en) 2015-12-03
BR112016027352A2 (pt) 2017-08-15
ES2841308T3 (es) 2021-07-08
US20170190697A1 (en) 2017-07-06
PT3150578T (pt) 2021-01-18
AU2015268505B2 (en) 2017-11-23
US9981960B2 (en) 2018-05-29
MX386063B (es) 2025-03-18
EP3150578A4 (en) 2017-12-06
HUE052714T2 (hu) 2021-05-28
RU2669938C2 (ru) 2018-10-17
TW201625589A (zh) 2016-07-16
RU2016151381A3 (es) 2018-06-26
SG11201609864UA (en) 2016-12-29
DK3150578T3 (da) 2021-01-18
KR20170012413A (ko) 2017-02-02
EP3150578A1 (en) 2017-04-05
MY193597A (en) 2022-10-19
EP3150578B1 (en) 2020-10-14
AU2015268505C1 (en) 2018-04-05
RU2016151381A (ru) 2018-06-26
PL3150578T3 (pl) 2021-07-19
BR112016027352A8 (pt) 2021-06-29
AU2015268505A1 (en) 2017-01-12
CN106458887A (zh) 2017-02-22
CN106458887B (zh) 2020-10-30
PH12016502358A1 (en) 2017-02-13
PH12016502358B1 (en) 2019-09-13
JPWO2015182723A1 (ja) 2017-04-20

Similar Documents

Publication Publication Date Title
MX2016015641A (es) Compuesto de pirrolidina novedoso, y aplicación como agonista del receptor de melanocortina.
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
MX2019010446A (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
MX2017004200A (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
PE20140406A1 (es) Moleculas bifuncionales con actividad de reclutamiento de anticuerpos y actividad inhibitoria inicial contra el virus de la inmunodeficiencia humana
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
GT201200230A (es) Inhibidores del virus de la hepatitis c
AR094712A1 (es) Modificador de sabor dulce
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY35333A (es) Compuestos de azabencimidazol
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
MX378439B (es) Radiofarmaceuticos y agentes de radio-formacion de imagen a base de triazina.
MX381970B (es) Derivado de sulfonamida y composición farmacéutica que contiene el mismo.
MX386008B (es) Compuestos citotóxicos y antimitóticos, y métodos para utilizarlos.
MX2017011824A (es) Derivado de morfinano.
MX374426B (es) Sintesis de compuestos de triacetonadiamina mediante procedimiento de aminacion reductora de triacetonadiamina y derivados de los mismos.
CR20160448A (es) Nuevos derivados de piridina
CU24248B1 (es) Derivados de (piperidin-4-il)piperazina-1-carboxamida/carboxilato como antagonistas del receptor-h3
MX374383B (es) Derivados de carboxamida como inhibidores de smurf-1
CR20160562A (es) Péptidos como agonistas de la oxitocina
JOP20200030A1 (ar) مركب خماسي الحلقة